[News] 2023 ASH annual meeting

January, 01, 2024 | Select Oncology Journal Articles

Ibrahim Aldoss (City of Hope National Medical Center, Duarte, CA, USA) and colleagues presented results from the AUGMENT-101 trial (NCT04065399) testing revumenib, an inhibitor of the menin–KMT2A interaction. 94 patients aged 30 days or older with relapsed or refractory KMT2A-rearranged (KMT2Ar) acute leukaemia received revumenib at 163 mg (or 95 mg/m2 if bodyweight was <40 kg), orally every 12 h in 28-day cycles. Median age was 37·0 years (range 1·3–75·0); 78 (83%) had acute myeloid leukaemia (AML) and 16 (17%) had acute lymphocytic leukaemia (ALL) or mixed phenotype acute leukaemia.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy